News

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

Researchers at Sungkyunkwan University School of Medicine in Korea conducted a nationwide cohort study involving nearly 4 million adults.

Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States.

Researchers discovered a rare genetic variant that generates malformed proteins that change the stability of the membrane attack complex (MAC). 

Researchers recently examined data from the National Health and Nutrition Examination Survey (NHANES) to determine the link between serum vitamin D levels and the odds of developing different subt...

Researchers were examining why some people with a genetic predisposition develop age-related macular degeneration (AMD) while others with the genetic predisposition do not.

Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.

Researchers hope that these cells are ready to be studied in human clinical trials 

Researchers analyzed genetic data from more than 16,000 people with AMD, more than 50,000 people with COVID along with control groups.